Neuroprotection | News
OTR3 has initiated its Phase 2 clinical trial for OTR4132, a novel neuroprotector designed to enhance functional recovery in acute ischemic stroke patients following thrombectomy. A first-in-human pilot study, MATRISS, was conducted across three centers in France, evaluating six escalating doses. The results were promising, demonstrating favorable safety and efficacy [...]
